Margaret A. Horn - 07 Jan 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Chief Operating Officer
Signature
/s/ Jack Anders, as Attorney-in-fact for Margaret Horn
Issuer symbol
RVMD
Transactions as of
07 Jan 2026
Net transactions value
-$4,656,737
Form type
4
Filing time
09 Jan 2026, 16:20:44 UTC
Previous filing
18 Dec 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Horn Margaret A Chief Operating Officer C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as Attorney-in-fact for Margaret Horn 09 Jan 2026 0001294192

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $2,182,185 +51,406 +36% $42.45 192,459 07 Jan 2026 Direct F1, F2
transaction RVMD Common Stock Options Exercise $703,101 +23,594 +12% $29.80 216,053 07 Jan 2026 Direct F1, F2
transaction RVMD Common Stock Sale $5,310,471 -53,096 -25% $100.02 162,957 07 Jan 2026 Direct F1, F2, F3
transaction RVMD Common Stock Sale $2,056,622 -20,204 -12% $101.79 142,753 07 Jan 2026 Direct F1, F2, F4
transaction RVMD Common Stock Sale $174,930 -1,700 -1.2% $102.90 141,053 07 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -51,406 -98% $0.000000 1,094 07 Jan 2026 Common Stock 51,406 $42.45 Direct F1
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -23,594 -16% $0.000000 119,906 07 Jan 2026 Common Stock 23,594 $29.80 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025.
F2 Includes 61,226 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $100.00 to $100.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 This transaction was executed in multiple trades in prices ranging from $101.07 to $101.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.